Medgenics to Present at the Oppenheimer 24th Annual Healthcare Conference
December 04 2013 - 10:16AM
Business Wire
Medgenics, Inc. (NYSE MKT:MDGN and AIM:MEDU, MEDG) (the
Company), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, announces that Company management will
participate in the Oppenheimer 24th Annual Healthcare Conference
taking place from December 10-11, 2013 in New York City.
Michael Cola, President and Chief Executive Officer of
Medgenics, will present a corporate overview on Wednesday, December
11th at 4:30 p.m. Eastern time.
About Medgenics
Medgenics is developing and commercializing Biopump™, a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis, among others. For more information,
please visit www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
Medgenics, Inc.John Leaman,
CFOjohn.leaman@medgenics.comorLHAAnne Marie Fields,
212-838-3777afields@lhai.com@LHA_IR_PRorAbchurch CommunicationsAdam
Michael/Joanne Shears/Jamie Hooper+44 207 398
7719jamie.hooper@abchurch-group.comorOriel Securities (NOMAD &
Joint Broker)Jonathan Senior/Giles Balleny+44 207710 7617orSVS
Securities plc (Joint Broker)Alex Brearley+44 207 638-5600
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jul 2023 to Jul 2024